Galecto Stock (NASDAQ:GLTO)
Previous Close
$6.02
52W Range
$5.62 - $23.50
50D Avg
$9.09
200D Avg
$13.95
Market Cap
$7.77M
Avg Vol (3M)
$39.30K
Beta
1.25
Div Yield
-
GLTO Company Profile
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
GLTO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| CNTA | Centessa Pharmaceuticals plc |
| ALGS | Aligos Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| SPRO | Spero Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| CHRS | Coherus BioSciences, Inc. |
| AADI | Aadi Bioscience, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |